This cooperation between FOXA1 and GRHL2 in ER driven breast cancer cells also contributes toward the resistance to endocrine therapy via the upregulation of LYPD/AGR2 (a receptor/ligand complex) making it a promising targetable frontier in endocrine therapy-resistant tumors (Cocce et al., 2019; Figure 2). The gene discussed is ESR1; the disease is breast cancer.